# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Theodore Roosevelt (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI012-SYN
- Date: 2026-03-09
- Fictional facility: St. Posthumous Health Center
- Fictional author: Amos Kettering, MD
- Calendar frame: modern shifted

## What we are working on

- Wheeze, night cough, and breathlessness are limiting his training and his long days at work **S**
- Would rather control his asthma with exercise than with daily medicine **S**

## Your goals

- Asthma Control Test score of 20 or more by the three-month review. Target: 2026-06-08. Recorded outcome: ACT rose from 13 to 22. **S**
- FEV1 of 80 percent predicted or more on spirometry after stabilization. Target: 2026-06-08. Recorded outcome: FEV1 89 percent predicted with a normal FEV1/FVC ratio. **S**
- No exacerbation needing oral corticosteroids over the six months after starting controller therapy. Target: 2026-09-14. Recorded outcome: Not met: one moderate exacerbation with a cold in August needed a five-day prednisone course; the goal continues for the next six months. **S**
- Return to full boxing and rowing training without limiting symptoms. Target: 2026-06-08. Recorded outcome: Training fully by the three-month review, using one reliever inhalation before sessions. **S**

## What we agreed to do

- Stop reliever-only albuterol and start budesonide-formoterol maintenance-and-reliever therapy at Step 4 (two inhalations twice daily plus one as needed, up to 12 a day), with a spacer and inhaler-technique teaching. Guideline: Global Strategy for Asthma Management and Prevention, 2025 update (2025); 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020) **S**
- Written asthma action plan with symptom and peak-flow zones (green 80 percent or more of personal best, yellow 50 to 79 percent, red below 50 percent), reviewed at every visit and after every exacerbation. Guideline: Global Strategy for Asthma Management and Prevention, 2025 update (2025); 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020); CMID: Clinical Monitoring Intelligence Database, asthma monograph (2026) **S**
- Pulmonology referral to confirm the diagnosis, assess type 2 inflammation, and advise on exercise-induced symptoms, allergen measures, and treatment step. Guideline: Global Strategy for Asthma Management and Prevention, 2025 update (2025); 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020) **S**
- Asthma Control Test, inhaler technique, adherence, reliever use, triggers, and exacerbation history at every visit; review one to three months after starting controller therapy, then every three to twelve months, and within one week of any exacerbation; spirometry at diagnosis, three to six months after stabilization, then every one to two years. Guideline: Global Strategy for Asthma Management and Prevention, 2025 update (2025); 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020); CMID: Clinical Monitoring Intelligence Database, asthma monograph (2026) **S**
- Explain that exercise improves fitness but does not treat airway inflammation; take one reliever inhalation before boxing or rowing; use dust-mite-impermeable bedding covers once sensitization is shown. Guideline: Global Strategy for Asthma Management and Prevention, 2025 update (2025); 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020) **S**
- Yearly influenza vaccine, pneumococcal vaccination for chronic lung disease, and COVID-19 vaccination by CDC guidance. Guideline: CMID: Clinical Monitoring Intelligence Database, asthma monograph (2026); Summary of Risk-based Pneumococcal Vaccination Recommendations (2025) **S**

## Follow-up

- 2026-03-09: Primary care visit for frequent wheeze, night cough, and breathlessness during training **S**
- 2026-04-06: Four-week asthma review after starting maintenance-and-reliever therapy, with pulmonology consultation **S**
- 2026-06-08: Three-month asthma review with repeat spirometry **S**
- 2026-09-14: Six-month asthma review after a summer exacerbation **S**
- 2026-10-19: Periodic adult preventive visit **S**

This teaching document does not replace care from a qualified clinician.
